Nebivolol

Bystolic treats hypertension alone or with other antihypertensives. Blood-pressure lowering reduces cardiovascular risk across antihypertensive classes, but the label states no controlled trials demonstrate cardiovascular-event reduction specifically with Bystolic. The label does not approve treatment of angina, acute/recent MI or heart failure; its older heart-failure study is not an approval or preferred-treatment claim.

When planned discontinuation is appropriate, taper over 1–2 weeks when possible with prescriber observation and minimized physical activity; abrupt withdrawal can cause angina, MI or ventricular arrhythmia. Worsening angina/acute coronary insufficiency requires prompt clinician reassessment and possible temporary restart. Full PI section 17 advises taking only the next scheduled dose after a missed dose; appended patient leaflet says take when remembered unless close to next. These differ: obtain exact-package pharmacist instructions and never double; no universal catch-up dose is inferred.

Severe bradycardia; heart block greater than first degree; cardiogenic shock; decompensated cardiac failure; sick sinus syndrome unless a permanent pacemaker is present; severe hepatic impairment (Child-Pugh >B); or hypersensitivity to components.

The selected Bystolic label has no boxed warning. Its abrupt-cessation warning still describes potentially serious coronary events.

Reported trial reactions include headache, fatigue, dizziness, nausea, diarrhea, bradycardia and edema. Postmarketing reports include AV block, hypotension/syncope, bronchospasm, acute pulmonary edema/renal failure and hypersensitivity; frequency/causality cannot be reliably estimated. Overdose can cause severe bradycardia, hypotension, heart failure, hypoglycemia, bronchospasm or heart block: obtain immediate Poison Help/emergency assessment and monitored supportive treatment. Hemodialysis is not expected to enhance clearance because protein binding is high; do not use label overdose measures as a home protocol.

Other pressure-lowering drugs can add hypotension even when no pharmacokinetic interaction was found. Review OTC medicines and prescriptions before adding therapy; clinically titrate rather than equate absence of PK changes with absence of pharmacodynamic risk.

Start 2.5 mg/day for CrCl <30 or moderate hepatic impairment, with slow escalation. Severe hepatic impairment (Child-Pugh >B) is contraindicated; dialysis data are absent. Older age alone requires no label dose change, but comorbid renal/hepatic disease, conduction problems and co-medications still need review.

Human pregnancy data are insufficient to define developmental risk, and untreated hypertension also poses maternal/fetal risks. Third-trimester beta-blocker exposure can cause neonatal hypotension, bradycardia, hypoglycemia or respiratory depression; observe newborns accordingly. Human milk data are absent; because beta blockers may seriously affect nursing infants, Bystolic is not recommended during breastfeeding. Discuss an appropriate hypertension plan rather than abruptly withdraw treatment.

Pediatric safety/effectiveness is unestablished; selected patient leaflet states not approved below 18. Do not convert juvenile animal findings into a clinical pediatric dose. Decompensated failure is contraindicated; an older chronic-HF trial in patients over 70 does not establish a U.S. HF indication or a full HF treatment regimen.

Nebivolol preferentially blocks beta1 receptors in extensive metabolizers at doses ≤10 mg; poor metabolizers and higher doses have beta1 and beta2 blockade. It lacks intrinsic sympathomimetic activity and clinically relevant alpha1 blockade. Possible antihypertensive contributors include slower heart rate, reduced contractility/renin/sympathetic outflow and vasodilation; the exact response mechanism is not settled.

Peak plasma levels occur about 1.5–4 hours after dosing; food does not change relevant PK. Protein binding is about 98%. Glucuronidation and CYP2D6 oxidation produce active metabolites. Effective d-nebivolol half-life is about 12 hours in extensive and 19 hours in poor metabolizers; higher parent exposure in poor metabolizers does not alone mandate dose adjustment. Moderate liver/severe renal impairment lowers clearance; assess response and toxicity.

Follow blood pressure, pulse, dizziness/syncope and heart-failure signs during titration. ECG monitoring is needed with verapamil/diltiazem-type combinations; assess renal/hepatic status and CYP2D6 interactions. Monitor for hypoglycemia by symptoms other than tachycardia when diabetes, fasting or vomiting is present. No universal lab-frequency or home pulse stop-threshold is supplied.

Take daily as prescribed, with or without food. Do not stop or double after a missed dose; ask pharmacist to reconcile the two label instructions. Report breathing difficulty, rapid weight gain/edema, fainting or excessive slowing. Learn individual effects before driving; tell surgical teams and discuss pregnancy/breastfeeding before treatment changes.

5 mg tablet

Beige, triangular, biconvex and unscored; FL on one side, 5 on other.

Package

NDC 0456-1405-30 · bottle 30; AbbVie distribution, Allergan label.

U.S. status

Prescription hypertension treatment; no DEA schedule.

Selected tablets

2.5,5,10,20 mg nebivolol equivalent as hydrochloride.

Appearance

2.5 mg light blue,5 mg beige,10 mg pinkish-purple,20 mg light blue; FL and strength markings.

Scope

No approved pediatric liquid, injection or automatically equivalent fixed combination is inferred.

Store 20–25°C. Dispense in tight, light-resistant container with child-resistant closure. Keep out of children’s reach and retain exact-package patient instructions; no unsupported refrigeration or splitting instruction is supplied.